ClinicalTrials.gov
ClinicalTrials.gov Menu

Identifying Barriers and Strategies to Support Self-efficacy for Medication Adherence With Text Messaging

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02785848
Recruitment Status : Recruiting
First Posted : May 30, 2016
Last Update Posted : August 8, 2018
Sponsor:
Information provided by (Responsible Party):
Robert Cronin, Vanderbilt University

Brief Summary:
The investigators will explore barriers to improving self-efficacy, or the ability to feel in control of their disease, and medication adherence with text messaging through surveys and interviews with adolescents and adults with SCD cared for at the Vanderbilt Meharry Center of Excellence (VMCE) in Sickle Cell Disease (SCD). The investigators will identify preferences to improve and sustain adherence to daily medication through selection of investigator-proposed or patient-generated text messaging strategies. Finally, the investigators will fill in the literature gaps by describing barriers to self-efficacy and medication adherence among adults with SCD as well as adolescents with SCD who are transitioning to adult care.

Condition or disease Intervention/treatment
Sickle Cell Disease Other: Interviews and Surveys

Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Identifying Patient-centered Barriers and Preferred Strategies to Support Self-efficacy for Medication Adherence With Two-way Text Messaging
Study Start Date : May 2016
Estimated Primary Completion Date : May 2019
Estimated Study Completion Date : May 2019

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Asthma and/or Sickle Cell Anemia
The investigators will examine patients with sickle cell disease, asthma, or both who are aged 12-70 years who take daily medications.
Other: Interviews and Surveys
The investigators will perform semi-structured interviews and surveys on this cohort




Primary Outcome Measures :
  1. Number of patients with barriers to medication adherence [ Time Frame: 1 year ]
    High cost, forgetting, side effects, access to medications


Secondary Outcome Measures :
  1. Number of patients that prefer a tailored text messaging technological solution [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The investigators will assess barriers to self-efficacy and medication adherence in the adolescents and adults with sickle cell disease (SCD), asthma, or both, who take daily medications such as hydroxyurea, asthma, or both, have access to mobile phones and/or computers and receive care at the VUMC/Matthew Walker clinic.
Criteria

Inclusion Criteria:

  1. Receiving care at the VUMC/Matthew Walker clinic
  2. Diagnosed with SCD, asthma, or both
  3. Currently taking daily medications for SCD, such as hydroxyurea, asthma, or both
  4. Having access to a mobile telephone and/or computer
  5. Age 12-70 years

Exclusion Criteria:

1. Unable to perform interviews or surveys


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02785848


Contacts
Contact: Robert Cronin, MD, MS 6159365097 robert.cronin@vanderbilt.edu

Locations
United States, Tennessee
Vanderbilt University Recruiting
Nashville, Tennessee, United States, 37203
Contact: Robert Cronin, MD, MS    615-936-5097    robert.cronin@vanderbilt.edu   
Contact: Michael DeBaun, MD, MPH    (615) 875-3040    m.debaun@vanderbilt.edu   
Sponsors and Collaborators
Vanderbilt University
Investigators
Principal Investigator: Robert Cronin, MD, MS Vanderbilt University

Responsible Party: Robert Cronin, Assistant Professor, Vanderbilt University
ClinicalTrials.gov Identifier: NCT02785848     History of Changes
Other Study ID Numbers: 160750
First Posted: May 30, 2016    Key Record Dates
Last Update Posted: August 8, 2018
Last Verified: August 2018

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn